132 related articles for article (PubMed ID: 16528479)
1. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Knowling M; Blackstein M; Tozer R; Bramwell V; Dancey J; Dore N; Matthews S; Eisenhauer E
Invest New Drugs; 2006 Sep; 24(5):435-9. PubMed ID: 16528479
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Ernst DS; Eisenhauer E; Wainman N; Davis M; Lohmann R; Baetz T; Belanger K; Smylie M
Invest New Drugs; 2005 Dec; 23(6):569-75. PubMed ID: 16034524
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Figg WD; Monga M; Headlee D; Shah A; Chau CH; Peer C; Messman R; Elsayed YA; Murgo AJ; Melillo G; Ryan QC; Kalnitskiy M; Senderowicz AM; Hollingshead M; Arbuck SG; Sausville EA
Cancer Chemother Pharmacol; 2014 Nov; 74(5):955-67. PubMed ID: 25183650
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Van Ummersen L; Binger K; Volkman J; Marnocha R; Tutsch K; Kolesar J; Arzoomanian R; Alberti D; Wilding G
Clin Cancer Res; 2004 Nov; 10(22):7450-6. PubMed ID: 15569974
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Marsh Rde W; Rocha Lima CM; Levy DE; Mitchell EP; Rowland KM; Benson AB
Am J Clin Oncol; 2007 Feb; 30(1):26-31. PubMed ID: 17278891
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of perifosine in androgen independent prostate cancer.
Posadas EM; Gulley J; Arlen PM; Trout A; Parnes HL; Wright J; Lee MJ; Chung EJ; Trepel JB; Sparreboom A; Chen C; Jones E; Steinberg SM; Daniels A; Figg WD; Dahut WL
Cancer Biol Ther; 2005 Oct; 4(10):1133-7. PubMed ID: 16138006
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
11. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
Shome D; Trent J; Espandar L; Hatef E; Araujo DM; Song CD; Kim SK; Esmaeli B
Ophthalmology; 2008 Mar; 115(3):483-7. PubMed ID: 18201764
[TBL] [Abstract][Full Text] [Related]
12. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
[TBL] [Abstract][Full Text] [Related]
13. Perifosine in renal cell carcinoma.
Srivastava N; Cho DC
Expert Opin Investig Drugs; 2013 Feb; 22(2):285-91. PubMed ID: 23253151
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
Matsumoto K; Shichino H; Kawamoto H; Kosaka Y; Chin M; Kato K; Mugishima H
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521076
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
[TBL] [Abstract][Full Text] [Related]
16. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Ghobrial IM; Roccaro A; Hong F; Weller E; Rubin N; Leduc R; Rourke M; Chuma S; Sacco A; Jia X; Azab F; Azab AK; Rodig S; Warren D; Harris B; Varticovski L; Sportelli P; Leleu X; Anderson KC; Richardson PG
Clin Cancer Res; 2010 Feb; 16(3):1033-41. PubMed ID: 20103671
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Eur J Cancer; 1993; 29A(2):208-9. PubMed ID: 8422284
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of 10-EDAM in advanced soft tissue sarcoma. A study of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.
Knowling M; Bramwell V; Eisenhauer E; Boos G; Bodurtha A; Quirt I
Ann Oncol; 1994 Oct; 5(8):766-8. PubMed ID: 7826912
[TBL] [Abstract][Full Text] [Related]
19. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
20. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Patel SR; Beach J; Papadopoulos N; Burgess MA; Trent J; Jenkins J; Benjamin RS
Cancer; 2003 Jun; 97(11):2848-52. PubMed ID: 12767099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
